MitraClip Therapy in Daily Clinical Practice: Initial Results from the German Transcatheter Mitral Valve Interventions (TRAMI) Registry
Key result
MitraClip therapy achieved procedural success in 94% of high-risk patients with significant mitral regurgitation, reducing grade III MR from 93% at baseline to 6% post-intervention.
Why the study?
Does percutaneous edge-to-edge therapy using MitraClip provide procedural success and safety in high surgical risk patients with significant mitral regurgitation?
Population
486 patients with significant mitral regurgitation considered high surgical risk, median age 75, 41% women…
Design
Cohort
Follow-up
median 183 days for retrospective patients, median 44 days…
Authors
Discussion
Loading...
Member takes
Implication
Supports MitraClip feasibility in high-risk MR; leaves open long-term outcomes versus surgery or medical therapy.
Study Design
Type
Cohort (n=486)
Multicenter
Yes
Structured PICO
Does percutaneous edge-to-edge therapy using MitraClip provide procedural success and safety in high surgical risk patients with significant mitral regurgitation?
P
Population
486 high surgical risk patients with significant mitral regurgitation (93% NYHA class III/IV) treated with MitraClip in a German registry, followed for a median of 44 to 183 days.
E
Exposure
Percutaneous edge-to-edge therapy for mitral regurgitation using the MitraClip
O
Outcome
Acute outcomes including procedural success, periprocedural complications, and mortality (in-hospital and post-discharge)
MitraClip therapy demonstrates high procedural success and acceptable safety in high surgical risk patients with significant mitral regurgitation in a real-world registry.
Cite This Study
Baldus et al. (2012) conducted a cohort in Mitral regurgitation (n=486). MitraClip was evaluated on Procedural success. MitraClip therapy achieved procedural success in 94% of high-risk patients with significant mitral regurgitation, reducing grade III MR from 93% at baseline to 6% post-intervention.